JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Kodu・Aktsiate loetelu・CorMedix Inc

CorMedix Inc

Suletud

SektorTervishoid

11.12 -4.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.91

Max

11.24

Põhinäitajad
By Trading Economics
Sissetulek	-816K 20M
Müük	655K 40M
P/E Sektori keskmine	14.167 37.003
Aktsiakasum	0.28
Kasumimarginaal	49.898
Töötajad	64
EBITDA	-297K 21M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+70.71% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-49M 872M
Eelmine avamishind	15.59
Eelmine sulgemishind	11.12

Uudiste sentiment

By Acuity

34%

66%

80 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

9.2 / N/A Toetus ja vastupanu

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. nov 2025, 22:13 UTC

Tulu

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2. nov 2025, 21:23 UTC

Tulu

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2. nov 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2. nov 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2. nov 2025, 21:00 UTC

Tulu

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2. nov 2025, 21:00 UTC

Tulu

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2. nov 2025, 21:00 UTC

Tulu

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Business Lending Up 15% on Year>WBC.AU

2. nov 2025, 20:46 UTC

Tulu

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2. nov 2025, 20:46 UTC

Tulu

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2. nov 2025, 20:45 UTC

Tulu

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2. nov 2025, 20:44 UTC

Tulu

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2. nov 2025, 20:43 UTC

Tulu

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2. nov 2025, 20:42 UTC

Tulu

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2. nov 2025, 20:41 UTC

Tulu

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2. nov 2025, 20:40 UTC

Tulu

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2. nov 2025, 20:39 UTC

Tulu

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2. nov 2025, 20:36 UTC

Tulu

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2. nov 2025, 20:34 UTC

Tulu

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2. nov 2025, 20:33 UTC

Tulu

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2. nov 2025, 14:27 UTC

Tulu

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2. nov 2025, 14:25 UTC

Tulu

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

70.71% tõus

12 kuu keskmine prognoos

Keskmine 19 USD 70.71%

Kõrge 22 USD

Madal 14 USD

Põhineb 7 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi CorMedix Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

80 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.